FGF-18 Compound Therapy for Rapid Osteoarthritis Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis, particularly for patients at risk of rapid progression, fail to effectively limit structural progression and manage pain, with existing surgical methods being unpredictable and ineffective in the long term.
Innovation Solution
Administration of an FGF-18 compound, specifically for patients with significant structural defects and non-acceptable joint pain, as determined by joint space width and pain scores, to inhibit cartilage thinning and alleviate clinical symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If microfracture surgery is performed to stimulate cartilage deposition, then bone marrow derived stem cells are stimulated to deposit cartilage, but the new cartilage formed is mainly fibrocartilage which does not have the same durability and may not adhere correctly to the surrounding hyaline cartilage
Solution Approach 1:
The invention changes the biological parameters of cartilage repair by using FGF-18 compound to stimulate chondrocyte proliferation and hyaline cartilage formation, rather than relying on bone marrow derived stem cells that produce fibrocartilage. This parameter change in the cellular mechanism transforms the quality and durability of the repaired cartilage.
2Object-affected harmful factors
If total joint replacement is performed to provide relief for advanced osteoarthritis, then symptom relief is achieved, but the procedure generally requires a change in a subject's lifestyle and/or activity level
Solution Approach 1:
The invention applies preliminary action by treating osteoarthritis at early stages (KL grade 1-2) before advanced damage occurs, using FGF-18 compound to prevent progression to severe stages that would require joint replacement and lifestyle changes. This preventive approach maintains natural joint function and preserves lifestyle.
3Object-affected harmful factors
If non-steroidal anti-inflammatory drugs are used to relieve osteoarthritis pain and decrease joint swelling, then clinical symptoms are managed, but their use may be limited by stomach irritation
Solution Approach 1:
The invention substitutes the mechanical/chemical action of NSAIDs on pain pathways with a biological mechanism - FGF-18 compound administration that directly stimulates cartilage repair and reduces inflammation at the source, thereby managing pain and swelling without the gastrointestinal side effects of NSAID medication.
4Loss of time
If surgical treatment is postponed for as long as possible in younger subjects, then surgical intervention is delayed, but the structural progression of the disorder continues unchecked
Solution Approach 1:
The invention enables preliminary action by providing early intervention with FGF-18 compound at KL grade 1-2 osteoarthritis, stimulating cartilage repair before significant structural damage occurs. This prevents the need for future surgical intervention while maintaining cartilage structural integrity, resolving the contradiction between delaying surgery and preserving cartilage structure.
Data Source
AI summary
The invention pertains to active compounds, in particular FGF-18 compounds, for use in the treatment of patients affected with a cartilage disorder, preferably osteoarthritis (OA), in particular for the treatment of patients who are at risk of rapid progression of the disorder.